Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2003

View Archived Issues

Advances at Celltech summarized in preliminary announcement of 2002 results

New COX-2 inhibitors and their use patented by Pharmacia

Novel agents with AGE-breaking, AGE-inhibitory and free radical-scavenging activity

Shionogi BioResearch claims compounds with Taxol-enhancing activity

MitoKor synthesizes and tests new antiarthritic agents

Novel platelet ADP receptor inhibitors in Millennium development pipeline

Mochida researchers present novel tryptase inhibitors

Newly discovered thrombin inhibitors patented by Merck

Immunosuppressants from AstraZeneca with utility in obstructive airways diseases

Novel selective alpha4 integrin inhibitors covered by Celltech patent

Promising anticonvulsant activity of agmatine in rat seizure model

Selective NCX inhibitor reduces myocardial ischemic injury in rabbits

Zelandopam prevents cisplatin-induced renal failure in rats

Altana reports key product progress

Paxceed produces positive response in psoriasis patients

Preliminary phase II results, IND submitted for exenatide LAR in type 2 diabetes

Lantus approved in E.U. for pediatric use

OncoMab and Medarex join forces for cancer antibody development

Genzyme begins enrollment for Myozyme trial in Pompe's disease

Aderis receives DTI-0009 development milestone payment

New data on the safety profile of tadalafil in erectile dysfunction

WHO coordinates research on mysterious pneumonia-like disease

Promising preclinical findings for aplidine in leukemia and lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...